BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Rueda PM, López-Nevot MÁ, Sáenz-López P, Casado J, Martín-Casares A, Palomares P, Quiles R, Gila A, Romero-Gómez M, Pavón EJ, Muñoz JA, Carazo A, Sanz-Cameno P, Moreno-Otero R, Diago M, León J, Ruiz-Extremera A, Salmerón J. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am J Gastroenterol 2011;106:1246-54. [PMID: 21670772 DOI: 10.1038/ajg.2011.82] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Frías M, Rivero-juárez A, Machuca I, Camacho Á, Rivero A. The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. Expert Review of Precision Medicine and Drug Development 2020;5:253-63. [DOI: 10.1080/23808993.2020.1764346] [Reference Citation Analysis]
2 Arshad M, Jalil I, Raza A, Malik S, Dasti JI. Novel Polymorphism in the Promoter Region of HLA-DQB1 Is a Predictor of Anti-HCV Therapy Response. Jundishapur J Microbiol 2019;12. [DOI: 10.5812/jjm.92217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Frias M, Rivero-Juárez A, López-López P, Rivero A. Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients. Pharmacogenomics 2018;19:979-95. [PMID: 29992850 DOI: 10.2217/pgs-2018-0046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
4 Muñoz de Rueda P, Jiménez-Ruiz SM, Quiles R, Pavón-Castillero EJ, Muñoz-Gámez JA, Casado J, Gila A, Ruiz-Extremera A, Salmerón J. The antigenic variability of HCV in viral HLA-Ag binding is related to the activation of the host immune response. Sci Rep 2017;7:15513. [PMID: 29138492 DOI: 10.1038/s41598-017-15605-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 López-Rodríguez R, Hernández-Bartolomé Á, Borque MJ, Rodríguez-Muñoz Y, Martín-Vílchez S, García-Buey L, González-Moreno L, Real-Martínez Y, Muñoz de Rueda P, Salmerón J, Vidal-Castiñeira JR, López-Larrea C, Rodrigo L, Moreno-Otero R, Sanz-Cameno P. Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C. PLoS One 2017;12:e0180927. [PMID: 28704535 DOI: 10.1371/journal.pone.0180927] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ruiz-Extremera A, Pavón-Castillero EJ, Florido M, Muñoz de Rueda P, Muñoz-Gámez JA, Casado J, Carazo A, Quiles R, Jiménez-Ruiz SM, Gila A, Luna JD, León J, Salmerón J. Influence of HLA class I, HLA class II and KIRs on vertical transmission and chronicity of hepatitis C virus in children. PLoS One 2017;12:e0172527. [PMID: 28225833 DOI: 10.1371/journal.pone.0172527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
7 Waldron PR, Belitskaya-Lévy I, Chary A, Won J, Winters M, Monto A, Ryan J, Lazzeroni LC, Holodniy M. Genetic Variation in the IL-6 and HLA-DQB1 Genes Is Associated with Spontaneous Clearance of Hepatitis C Virus Infection. J Immunol Res 2016;2016:6530436. [PMID: 27340680 DOI: 10.1155/2016/6530436] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
8 Xu Y, Huang P, Yue M, Su J, Chen H, Chen M, Wang J, Li J, Peng Z, Zhang Y, Yu R. A novel polymorphism near HLA class II region is associated with spontaneous clearance of HCV and response to interferon treatment in Chinese patients. J Hum Genet 2016;61:301-5. [PMID: 26632884 DOI: 10.1038/jhg.2015.145] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
9 Cariani E, Roli L, Missale G, Villa E, Ferrari C, Trenti T. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. Pharmacogenomics J. 2015;Epub ahead of print. [PMID: 25918016 DOI: 10.1038/tpj.2015.28] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
10 Riva E, Scagnolari C, Turriziani O, Antonelli G. Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response to antiviral treatment. Clin Microbiol Infect 2014;20:1237-45. [PMID: 25273834 DOI: 10.1111/1469-0691.12797] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
11 Quiles-pérez R, Pavón-castillero EJ, Muñoz-de-rueda P, Carmona I, Salmerón J. Valor de la genética en la era de la terapia triple frente al virus de la hepatitis C. Gastroenterología y Hepatología 2014;37:427-37. [DOI: 10.1016/j.gastrohep.2014.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
12 Thomas BS, Joyce MA, Levin A, Tyrrell DL. Validation of TaqMan® SNP genotyping specificity for rs12979860 of IL-28B: modeling primer specificity in vitro. J Virol Methods 2014;203:39-47. [PMID: 24681052 DOI: 10.1016/j.jviromet.2014.03.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
13 Sato M, Kondo M, Tateishi R, Fujiwara N, Kato N, Yoshida H, Taguri M, Koike K. Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. PLoS One 2014;9:e91822. [PMID: 24637774 DOI: 10.1371/journal.pone.0091822] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
14 Ruiz-Extremera A, Muñoz-Gámez JA, Abril-Molina A, Salmerón-Ruiz MA, Muñoz-de-Rueda P, Pavón-Castillero EJ, Quiles-Pérez R, Carazo A, Gila A, Jimenez-Ruiz SM, Casado J, Martín AB, Sanjuán-Núñez L, Ocete-Hita E, Viota JL, León J, Salmerón J. Variation of transaminases, HCV-RNA levels and Th1/Th2 cytokine production during the post-partum period in pregnant women with chronic hepatitis C. PLoS One 2013;8:e75613. [PMID: 24130726 DOI: 10.1371/journal.pone.0075613] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
15 Villar LM, Del Campo JA, Ranchal I, Lampe E, Romero-Gomez M. Association between vitamin D and hepatitis C virus infection: A meta-analysis. World J Gastroenterol 2013; 19(35): 5917-5924 [PMID: 24124339 DOI: 10.3748/wjg.v19.i35.5917] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 67] [Article Influence: 6.5] [Reference Citation Analysis]
16 Rangnekar AS, Fontana RJ. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis. J Viral Hepat 2013;20:377-84. [PMID: 23647954 DOI: 10.1111/jvh.12039] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
17 López-rodríguez R, Hernández-bartolomé Á, Borque MJ, Rodríguez-muñoz Y, Martín-vílchez S, Trapero-marugán M, García-buey L, Muñoz de Rueda P, Rodrigo L, Vidal-castiñeira JR, Salmerón J, Moreno-otero R, Sanz-cameno P. Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy. Genes Immun 2013;14:317-24. [DOI: 10.1038/gene.2013.24] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
18 Berger CT, Kim AY. IL28B polymorphisms as a pretreatment predictor of response to HCV treatment. Infect Dis Clin North Am 2012;26:863-77. [PMID: 23083820 DOI: 10.1016/j.idc.2012.08.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
19 Fernández-Rodríguez A, Jiménez-Sousa MÁ, Resino S. Comment on: 'interleukin-28 polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis'. Gene 2013;522:121. [PMID: 23506831 DOI: 10.1016/j.gene.2013.03.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Shaker O, Bassiony H, El Raziky M, El-Kamary SS, Esmat G, El-Ghor AM, Mohamed MM. Human leukocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4. Mediators Inflamm 2013;2013:392746. [PMID: 23576852 DOI: 10.1155/2013/392746] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
21 Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, García-Álvarez M, Resino S. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med. 2013;11:6. [PMID: 23298311 DOI: 10.1186/1741-7015-11-6] [Cited by in Crossref: 64] [Cited by in F6Publishing: 74] [Article Influence: 6.4] [Reference Citation Analysis]
22 Pavón-Castillero EJ, Muñoz-de-Rueda P, López-Segura R, Gila A, Quiles R, Muñoz-Gámez JA, Carazo A, Martínez P, Ruiz-Extremera A, Salmerón J. Importance of IL-10 and IL-6 during chronic hepatitis C genotype-1 treatment and their relation with IL28B. Cytokine 2013;61:595-601. [PMID: 23159283 DOI: 10.1016/j.cyto.2012.10.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
23 Jia Z, Ding Y, Tian S, Niu J, Jiang J. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis. PLoS One. 2012;7:e45698. [PMID: 23029188 DOI: 10.1371/journal.pone.0045698] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
24 Schreiber J, Moreno C, Garcia BG, Louvet A, Trepo E, Henrion J, Thabut D, Mathurin P, Deltenre P. Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients. Aliment Pharmacol Ther 2012;36:353-62. [PMID: 22742526 DOI: 10.1111/j.1365-2036.2012.05197.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
25 Shi KQ, Liu WY, Lin XF, Fan YC, Chen YP, Zheng MH. Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis. Gene 2012;507:27-35. [PMID: 22842190 DOI: 10.1016/j.gene.2012.07.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
26 Hayes CN, Imamura M, Aikata H, Chayama K. Genetics of IL28B and HCV--response to infection and treatment. Nat Rev Gastroenterol Hepatol 2012;9:406-17. [PMID: 22641049 DOI: 10.1038/nrgastro.2012.101] [Cited by in Crossref: 77] [Cited by in F6Publishing: 83] [Article Influence: 7.0] [Reference Citation Analysis]
27 Marangon AV, Moliterno RA, Sell AM, de Moraes CF, Grotto RM, Pardini MC, De Pauli DS, Visentainer JE, Silva GF. Influence of HLA alleles in response to treatment with pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C. Int J Immunogenet 2012;39:296-302. [PMID: 22284614 DOI: 10.1111/j.1744-313X.2012.01088.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
28 Lopez-Rodriguez R, Trapero-Marugan M, Borque MJ, Roman M, Hernandez-Bartolome A, Rodriguez-Muñoz Y, Martin-Vilchez S, Abad-Santos F, Muñoz de Rueda P, Vidal-Castiñeira JR, Rodrigo L, Salmeron J, Moreno-Otero R, Sanz-Cameno P. Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C. Clin Pharmacol Ther 2011;90:712-21. [PMID: 21993426 DOI: 10.1038/clpt.2011.189] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
29 Ott SJ, Schreiber S. [Genetic susceptibility to infections]. Internist (Berl) 2011;52:1053-4, 1056-8, 1060. [PMID: 21842176 DOI: 10.1007/s00108-011-2858-8] [Reference Citation Analysis]